Skip to main content

Advertisement

SpringerLink
Log in

Glucocorticoid excess and hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Cushing’s syndrome is a rare disorder characterized by chronic, excess glucocorticoid exposure. Hypertension is one of the most discriminating features of the disease, as it is present in 80% of patients. Patients with Cushing’s syndrome have a mortality rate four times that of the general population, most likely secondary to an increased number of cardiovascular risk factors, including hypertension. In this article, we review several pathogenetic mechanisms of glucocorticoid-induced hypertension, including the role of sodium/water and mineralocorticoid excess, as well as involvement of the vasculature and kidney. Although treatment of hypertension with available antihypertensive medications is only moderately successful, after cure of Cushing’s syndrome, approximately 30% of patients have persistent hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Arnoldi G, Angeli A, Atkinson AB, et al.: Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593–5602.

    Article  CAS  Google Scholar 

  2. Ross EJ, Linch DC: Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982, 2:646–649.

    Article  PubMed  CAS  Google Scholar 

  3. Stewart PM, Walker BR, Holder F: 11 beta-hydroxysteroid dehydrogense activity in Cushing’s syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995, 80:3617–3620.

    Article  PubMed  CAS  Google Scholar 

  4. Magiakou MA, Mastorakos G, Zachman K, et al.: Blood pressure in children and adolescents with Cushing’s syndrome before and after surgical cure. J Clin Endocrinol Metab 1997, 82:1734–1738.

    Article  PubMed  CAS  Google Scholar 

  5. Fraser R, Davies DL, Connell JMC: Hormones and hypertension. Clin Endocrinol 1989, 31:701–746. Changes in hormone secretion in human hypertension are reviewed, key papers are summarized, and controversial theories in the pathogenesis of glucocorticoid-induced hypertension and other forms of hormonal hypertension are discussed.

    CAS  Google Scholar 

  6. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252. This report provides an evidence-based approach to the prevention and management of hypertension.

    Article  PubMed  CAS  Google Scholar 

  7. Extabe J, Vazquez JA: Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479–484.

    Google Scholar 

  8. Torpy DJ, Mullen N, Ilias I, et al.: Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann N Y Acad Sci 2002, 970:134–144. This retrospective case review of 58 patients with ectopic ACTH secretion identifies common causes of this condition and reviews the incidence and prevalence of hypertension and hypokalemia in these patients.

    PubMed  CAS  Google Scholar 

  9. Faggiano A, Pivonello R, Spiezia S, et al.: Cardiovascular risk factors and common carotid artery caliber and stiffness inpatients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88:2527–2533.

    Article  PubMed  CAS  Google Scholar 

  10. Panarelli M, Terzolo M, Piovesan A, et al.: 24-hour profiles of blood pressure and heart rate in Cushing’s syndrome: evidence for differential control of cardiovascular variables by glucocorticoids. Ann Ital Med Int 1990, 5:18–25.

    PubMed  CAS  Google Scholar 

  11. Zelinka T, Strauch B, Pecen L, et al.: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing’s syndrome. J Hum Hypertens 2004, 18:107–111.

    Article  PubMed  CAS  Google Scholar 

  12. Hatakeyama H, Inaba S, Miyamori I: 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension. Hypertension 1999, 33:1179–1184.

    PubMed  CAS  Google Scholar 

  13. Brem A, Bina R, King T, et al.: Localization of 2 11 beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31:459–462.

    PubMed  CAS  Google Scholar 

  14. Ritchie CM, Sheridan B, Fraser R, et al.: Studies on the pathogenesis of hypertension in Cushing’s disease and acromegaly. Q J Med 1990, 280:855–867.

    Google Scholar 

  15. Ulick S, Wang JZ, Blumenfeld JD, et al.: Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metabol 1992, 74:963–967.

    Article  CAS  Google Scholar 

  16. Quinkler M, Stewart PM: Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003, 88:2384–2392. The role of the cortisol-cortisone shuttle in human hypertension is reviewed. Specifically, SAME, ectopic ACTH production, and polymorphic variability in the HSD11B2 gene are discussed.

    Article  PubMed  CAS  Google Scholar 

  17. Dotsch J, Dorr HG, Stall GK, et al.: Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 2001, 66:817–820.

    Article  PubMed  CAS  Google Scholar 

  18. Ferrari P, Krozowski Z: Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000, 57:1374–1381.

    Article  PubMed  CAS  Google Scholar 

  19. Farman N, Bocchi B: Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000, 57:1364–1369.

    Article  PubMed  CAS  Google Scholar 

  20. Connell JM, Whitworth JA, Davies DL, et al.: Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987, 5:425–433.

    Article  PubMed  CAS  Google Scholar 

  21. Mangos GJ, Whitworth JA, Williamson PM: Glucocorticoids and the kidney. Nephrology 2003, 8:267–273. The effect of glucocorticoids on renal metabolism, hemodynamics, and the role of the kidney in glucocorticoid hypertension are discussed.

    Article  PubMed  CAS  Google Scholar 

  22. Whitworth JA, Gordon D, Andrews J, et al.: The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537–549.

    Article  PubMed  CAS  Google Scholar 

  23. Nieman LK, Chrousos GP, Kellner C, et al.: Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985, 61:536–540.

    PubMed  CAS  Google Scholar 

  24. Sala C, Ambrosi B, Morganti A: Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing’s disease. J Clin Endocrinol Metab 2001, 86:1957–1961.

    Article  PubMed  CAS  Google Scholar 

  25. Yasunari K, Kohno M, Murakawa K, et al.: Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension 1990, 16:581–586.

    PubMed  CAS  Google Scholar 

  26. Kelm M: The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 2003, 5:80–86.

    Article  PubMed  Google Scholar 

  27. Axelrod L: Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing’s syndrome and Addison’s disease. Lancet 1983, 23:904–906.

    Article  Google Scholar 

  28. Saruta T, Suzuki H, Handa M, et al.: Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrinol Metab 1986, 62:275–279.

    PubMed  CAS  Google Scholar 

  29. Scheuer DA, Becht AG: Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1719-R1726.

    PubMed  CAS  Google Scholar 

  30. Pirpiris, M, Sudhir K, Yeung S, et al.: Pressor responsiveness in corticosteroid-induced hypertension in humans. J Hypertens 1989, 7:537–549.

    Article  Google Scholar 

  31. McKnight JA, Rooney DP, Whitehead H, et al.: Blood pressure responses to phenylephrine infusions in subjects with Cushing’s syndrome. J Hum Hypertens 1995, 9:855–858.

    PubMed  CAS  Google Scholar 

  32. Sato A, Suzuki H, Murakami M, et al.: Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994, 23:25–30.

    PubMed  CAS  Google Scholar 

  33. Arai H, Hori S, Aramori I, et al.: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730–732.

    Article  PubMed  CAS  Google Scholar 

  34. Kirilov G, Tomova A, Dakovska L, et al.: Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 2003, 149:549–553.

    Article  PubMed  CAS  Google Scholar 

  35. Quaschning T, Ruschitzka F, Niggli B, et al.: Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 2001, 16:2146–2151.

    Article  PubMed  CAS  Google Scholar 

  36. Shelat, SG, King JL, Flanagan-Cato LM, et al.: Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology 1999, 69:339–351.

    Article  PubMed  CAS  Google Scholar 

  37. Van Uum SH, Houben AJ, Hermus AR, et al.: Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. J Hypertens 2002, 20:2275–2283.

    Article  PubMed  Google Scholar 

  38. Zimmerman BG, Dunham EW.: Tissue renin-angiotensin system: A site of drug action? Ann Rev Pharmacol Toxicol 1997, 37:53–69.

    Article  CAS  Google Scholar 

  39. Nishiyama A, Fujisawa Y, Fukui T, et al.: Role of nitric oxide in regional blood flow in angiotensin II-induced hypertensive rats. Hypertens Res 2001, 24:421–427.

    Article  PubMed  CAS  Google Scholar 

  40. Souness GW, Brem AS, Morris DJ: 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002, 67:195–201.

    Article  PubMed  CAS  Google Scholar 

  41. Donmez G, Derici U, Erbas D, et al.: The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol 2002, 52:435–440.

    Article  PubMed  CAS  Google Scholar 

  42. Tsikouris JP, Cox CD: Pharmacologic blockade of the reninangiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 2003, 23:1141–1152.

    Article  PubMed  CAS  Google Scholar 

  43. Di Girolamo G, Gonzalez E, Livio D, et al.: The effect of enalapril on PGI(2) and NO levels in hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 2002, 66:493–498.

    Article  PubMed  Google Scholar 

  44. Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004, 27:129–135.

    Article  PubMed  CAS  Google Scholar 

  45. Dalakos TG, Elias AN, Anderson GH Jr, et al.: Evidence for an angiotensinogenic mechanism of the hypertension of Cushing’s syndrome. J Clin Endocrinol Metab 1978, 46:114–118.

    PubMed  CAS  Google Scholar 

  46. Zacharieva S, Orbetzova M, Natchev E, et al.: Losartan in Cushing’s syndrome. Methods Find Exp Clin Pharmacol 1998, 20:163–168.

    Article  PubMed  CAS  Google Scholar 

  47. Fallo F, Paoletta A, Tona F, et al.: Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing’s syndrome. J Intern Med 1993, 234:595–598.

    Article  PubMed  CAS  Google Scholar 

  48. Fallo F, Sonino N, Barzon L, et al.: Effect of surgical treatment on hypertension in Cushing’s syndrome. Am J Hypertens 1996, 9:77–80.

    Article  PubMed  CAS  Google Scholar 

  49. Colao A, Pivonello R, Spiezia S, et al.: Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664–2672.

    Article  PubMed  CAS  Google Scholar 

  50. Seckl JR, Morton NM, Chapman KE, et al.: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004, 59:359–393.

    Article  PubMed  CAS  Google Scholar 

  51. Andrew R, Phillips DIW, Walker BR: Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998, 83:1806–1809.

    Article  PubMed  CAS  Google Scholar 

  52. Fraser R, Ingram MC, Anderson NH, et al.: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33:1364–1368.

    PubMed  CAS  Google Scholar 

  53. Stewart PM, Boulton A, Kumar S, et al.: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999, 84:1022–1027.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 9D42 MSC 1583, 10 Center Drive, 20892-1583, Bethesda, MD, USA

    Smita Baid MD & Lynnette K. Nieman MD

Authors
  1. Smita Baid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynnette K. Nieman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baid, S., Nieman, L.K. Glucocorticoid excess and hypertension. Current Science Inc 6, 493–499 (2004). https://doi.org/10.1007/s11906-004-0046-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-004-0046-0

Keywords

Search

Navigation